Why the study?
Does intravenous immunoglobulin (IVIG) neutralize beta1AR autoantibodies in patients with dilated cardiomyopathy and coronary artery disease?
Population
Patients with dilated cardiomyopathy (DCM) and coronary artery disease (CAD)
Comparison
Intravenous immunoglobulin (IVIG) vs Placebo
Design
RCT
Follow-up
12 months
Authors
Loading...
IVIG does not neutralize beta1AR autoantibodies in DCM; challenges this proposed mechanism and redirects research to alternative pathways of benefit.
Does intravenous immunoglobulin (IVIG) neutralize beta1AR autoantibodies in patients with dilated cardiomyopathy and coronary artery disease?
The beneficial effect of IVIG on cardiac function in cardiomyopathy is not mediated by the neutralization of beta1-adrenoceptor autoantibodies.
Larsson et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: